Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI - Wikidata - awgldk - TriplyDB

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

http://www.wikidata.org/entity/Q37419658

about

The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography Imago Mundi, Imago AD, Imago ADNI Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics.Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment.Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease.Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease Imaging biomarkers associated with cognitive decline: a review.Emerging β-amyloid pathology and accelerated cortical atrophy.The transitional association between β-amyloid pathology and regional brain atrophy Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models.Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations Early Prediction of Alzheimer's Disease Using Null Longitudinal Model-Based Classifiers.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study.Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study Twenty-five years of progress: the view from NIMH and NINDS Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.The Risk of Incident Mild Cognitive Impairment and Progression to Dementia Considering Mild Cognitive Impairment Subtypes.CSF Apo-E levels associate with cognitive decline and MRI changes Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State.Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly.Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Biomarkers in Neurodegenerative Diseases.Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

P2860

Q28088291-82C676A9-C812-4A00-88D4-870B4B72539B Q28273817-A19C7808-26A5-4568-883F-0E9D598FD4E4 Q28650395-20BBA93A-B189-4D02-A6B0-C5155203FFBC Q30244736-0F284367-B0FF-4CE0-9FE8-144CAD97500E Q30845482-B8BFC26A-1313-499E-841C-CF0D97E1C185 Q30971403-6E6E445B-E354-45BD-8130-224B3FCC05B4 Q33559175-D2052CF6-26E7-4ADF-8B69-608610A34BDF Q33687554-4970A631-C02C-41C1-B95F-7556C7C99ED6 Q33695122-FACFFF70-A24C-47D2-BC1B-331C3CAAD348 Q34630522-A5B5AE30-B0DC-4AD0-AD4D-DD1DC84DD839 Q34991746-1EDE1437-0BFA-49FA-B8EE-1BB15D3F59C7 Q35119389-F1D4D00E-6B6C-4540-8BB9-26743D25C48A Q35185786-B707B6D5-7696-4C24-9F7C-8A0556A878DD Q35542164-3F54E942-81EA-43B7-B8A4-757599DD958E Q35706871-4BB6FA72-9FF6-4D09-B870-BEC6EFC75D14 Q35904243-4A911D0E-FBCE-4433-AFEA-CFB1BB348F5D Q36062391-B082136E-C36D-4374-A1F8-EB4DFA860A4D Q36071742-14B3A102-E8B6-4A69-BF91-CB98CD152A30 Q36165011-014FE826-5980-4C8E-A832-B8EEB00FC2A7 Q36237796-763227C6-709D-44DE-AEBF-4B754BA87E97 Q36276506-E68C7195-92F0-4EF8-931A-1789CE9DF96B Q36353787-D22BB711-5A8C-460B-9BA9-E8D7FFDFF88B Q36933698-5B6B40EC-B960-413A-810B-BD322C8A22DA Q37384323-55EB2507-7D29-44A6-A4A6-2416701C934C Q37410700-01301A8E-DCFC-4073-9FDB-BEBAC35F5BE9 Q37414970-4B933113-613A-4D89-BD98-B28D66716BA4 Q37451440-EAF29433-C5C0-42A2-AF5D-E64926EE52DE Q37695131-A55D6DE4-38AB-4027-80BF-FF65EDCDFBD4 Q37705204-DCEF145F-19FA-4F69-8981-1B71F85DC2E9 Q38289739-C788DECB-D241-49F1-9F48-899F3D769419 Q38603309-177964D4-A8B8-4BAA-A3A9-7261473BAB61 Q38628805-6408D593-41CA-45E4-BF00-C89D55E54DF9 Q38629788-2D63D73D-8D19-4186-AA6F-28AF3736FD8F Q38815351-ECD57638-2B3A-4822-9419-431CC94A1816 Q38960660-C2D3E8BD-0D19-43CB-ADCE-796D094A6F44 Q38979999-CB992450-74C2-4DE7-89BC-F0C86E020D2B Q39413097-C9B4C86D-50F0-403D-8231-C88E6FF00859 Q39929112-892BCDC1-5D14-4ED6-B3D6-412CE942DCAF Q40101067-AB559AB3-8CDA-4DFF-BD46-BC90B9821FE8 Q40118660-118E9212-03F4-415A-AAE2-973D0F483210

P2860

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

http://www.wikidata.org/entity/Q37419658

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

@en

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.

@nl

type

label

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

@en

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.

@nl

prefLabel

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

@en

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.

@nl

P1433

Q37419658-B1C56923-1C82-4F6D-B72C-406096D5D54C

P1476

Q37419658-098051BF-F046-402A-85EF-ACB3256EBEE9

P2093

Q37419658-1E97D8E8-7480-4C3C-A997-6E701ED32AEF

Q37419658-7DA31734-4326-4535-B471-4CED4B609EE6

P2860

Q37419658-03E93BAA-3C9F-486D-8E29-4DF7A77AAE1C

Q37419658-04D20CC9-F7AB-44A3-9D26-A6143D6EB7B7

Q37419658-1C5199EB-B5C6-4D83-8B81-10827CF27649

Q37419658-2159A0E5-2BD4-41F1-A781-1F78D9C23FD5

Q37419658-263A3E94-D49C-41FE-B061-2BCD0F4B9B6F

Q37419658-2BEBE13F-68A9-4E36-9F3F-90D0210AAB8C

Q37419658-46A6BE49-355C-4FE7-BB8D-0389BFE2DE6E

Q37419658-563D062E-34B0-4A55-8D72-9914081FDFEE

Q37419658-57AD2560-A78D-474D-9424-AC8FC910F162

Q37419658-5D2460BD-7B2D-45B2-9AB2-59315D73EC62

P2888

Q37419658-52040102-2AA5-4E60-9E1B-027BCD36D74F

P304

Q37419658-A9EE8355-D25D-4AB9-ABC0-A6E0EAC8206C

P31

Q37419658-F886AD99-8CAB-4BC7-B860-3AB391EF059A

P356

Q37419658-C74A740F-D327-430E-A765-472DB36F09A1

P433

Q37419658-BC50FCA0-ACE3-4842-B5DB-1E7134035536

P478

Q37419658-36D85DC3-E521-42FD-AD75-CD9EC46851E3

P50

Q37419658-89BAF39D-D8D6-459E-A75A-C205EF8131D9

Q37419658-988EBE49-A868-4165-B5FA-ECEAD8FAD8AD

P577

Q37419658-B8CDB4B5-F422-4E11-A0CF-57055FA95177

P698

Q37419658-5F6653BC-1CC8-43AE-9247-0A0A896D4499

P921

Q37419658-45B186FB-BC91-4B05-82BD-1C59D4DF01CD

P932

Q37419658-6F8CE73B-4AA4-4C04-BE23-FEE95D9A3CA3

P356

S00401-013-1151-4

P1433

Acta Neuropathologica

P1476

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

@en

P2093

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Sharon X Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Purification and cloning of amyloid precursor protein beta-secretase from human brain

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Mild cognitive impairment: pathology and mechanisms.

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Mild cognitive impairment: clinical characterization and outcome

Random-effects models for longitudinal data

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

P2888

s00401-013-1151-4

P304

659-670

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-013-1151-4

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

John Q. Trojanowski

P577

2013-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23812320

http://www.w3.org/2001/XMLSchema#string

P921

P932

3875373

http://www.w3.org/2001/XMLSchema#string